Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Patients With Nonalcoholic Fatty Liver Disease: a Single Center, Double-blind, Randomized, Placebo-Controlled, Phase 2a Trial.

NCT04235205 is registered in ClinicalTrials.gov with Yokohama City University as lead sponsor.

NCT NCT04235205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04235205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Patients With Nonalcoholic Fatty Liver Disease: a Single Center, Double-blind, Randomized, Placebo-Controlled, Phase 2a Trial.
Lead sponsor
Yokohama City University
Phase
Phase 2
Overall status
Completed
Start date
January 29, 2020
Completion date
September 30, 2021
Enrollment
102 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic fatty liver, nonalcoholic steatohepatitis